FDA approves GEs mobile mammography system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved use of its mobile Senographe Essential, which the company said will improve access to breast cancer screening by offering full-field digital mammography in a mobile setting.

According to GE, the newest mobile unit features the largest digital detector in the mammography market, advanced ergonomic design for the technologist, optimized patient comfort and seamless workflow connectivity. The new unit also delivers high detective quantum efficiency at low doses.